Plasma lipoproteins in visceral leishmaniasis and their effect on Leishmania-infected macrophages

Parasite Immunology

Volumn 32, Issue 4, 2010, Pages 259-266

  Soares, Neci Matos ^a   Leal, T F ^a,b   Fiuza M C ^a,b   Reis, E A G ^b   Souza, M A L ^a   Dos Santos, W L ^b   Pontes De Carvalho, L ^b  

^a FEDERAL UNIVERSITY OF BAHIA   (Brazil)

^b INSTITUTO OSWALDO CRUZ   (Brazil)

Author keywords

Cytokines; Leishmania; Lipoproteins

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN B; CHOLESTEROL; HIGH DENSITY LIPOPROTEIN; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 6; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA; VERY LOW DENSITY LIPOPROTEIN;

ADULT; AGED; ARTICLE; CHILD; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; HUMAN; HUMAN CELL; IN VITRO STUDY; LIPOPROTEIN BLOOD LEVEL; MACROPHAGE; NONHUMAN; PRIORITY JOURNAL; TRIACYLGLYCEROL BLOOD LEVEL; ULTRACENTRIFUGATION; VISCERAL LEISHMANIASIS;

ADULT; ANIMALS; CHILD; CHILD, PRESCHOOL; CYTOKINES; FEMALE; HUMANS; INFANT; LEISHMANIASIS, VISCERAL; LIPIDS; LIPOPROTEINS; MACROPHAGES; MALE; ULTRACENTRIFUGATION; YOUNG ADULT;

LEISHMANIA INFANTUM;

EID: 77949447167     PISSN: 01419838     EISSN: 13653024     Source Type: Journal    
DOI: 10.1111/j.1365-3024.2009.01187.x     Document Type: Article

References (60)

1. Mauricio IL, Howard MK, Stothard JR & Miles MA. Genomic diversity in the Leishmania donovani complex. Parasitology 1999; 119(Pt 3): 237-246.
2. Andrade TM, Carvalho EM & Rocha H. Bacterial infections in patients with visceral leishmaniasis. J Infect Dis 1990; 162: 1354-1359.
3. Ho M, Koech DK, Iha DW & Bryceson AD. Immunosuppression in Kenyan visceral leishmaniasis. Clin Exp Immunol 1983; 51: 207-214.
4. Ho JL, Badaro R, Schwartz A, et al. Diminished in vitro production of interleukin-1 and tumor necrosis factor-alpha during acute visceral leishmaniasis and recovery after therapy. J Infect Dis 1992; 165: 1094-1102.
5. Cillari E, Liew FY, Lo Campo P, Milano S, Mansueto S & Salerno A. Suppression of IL-2 production by cryopreserved peripheral blood mononuclear cells from patients with active visceral leishmaniasis in Sicily. J Immunol 1988; 140: 2721-2726.
6. Mauricio IL, Stothard JR & Miles MA. The strange case of Leishmania chagasi. Parasitol Today 2000; 16: 188-189.
7. Bauzer LG, Souza NA, Maingon RD & Peixoto AA. Lutzomyia longipalpis in Brazil: a complex or a single species? A mini-review. Mem Inst Oswaldo Cruz 2007; 102: 1-12.
8. Rezai HR, Ardehali SM, Amirhakimi G & Kharazmi A. Immunological features of kala-azar. Am J Trop Med Hyg 1978; 27: 1079-1083.
9. Carvalho EM, Badaro R, Reed SG, Jones TC & Johnson WD Jr. Absence of gamma interferon and interleukin 2 production during active visceral leishmaniasis. J Clin Invest 1985; 76: 2066-2069.
10. Carvalho EM, Barral A, Pedral-Sampaio D, et al. Immunologic markers of clinical evolution in children recently infected with Leishmania donovani chagasi. J Infect Dis 1992; 165: 535-540.
11. Kurkjian KM, Mahmutovic AJ, Kellar KL, Haque R, Bern C & Secor WE. Multiplex analysis of circulating cytokines in the sera of patients with different clinical forms of visceral leishmaniasis. Cytometry A 2006; 69: 353-358.
12. Sanal O, Turkkani G, Gumruk F, et al. A case of interleukin-12 receptor beta-1 deficiency with recurrent leishmaniasis. Pediatr Infect Dis J 2007; 26: 366-368.
13. Barral-Netto M, Badaro R, Barral A, et al. Tumor necrosis factor (cachectin) in human visceral leishmaniasis. J Infect Dis 1991; 163: 853-857.
14. Engwerda CR, Ato M, Cotterell SE, et al. A role for tumor necrosis factor-alpha in remodeling the splenic marginal zone during Leishmania donovani infection. Am J Pathol 2002; 161: 429-437.
15. Caldas A, Favali C, Aquino D, et al. Balance of IL-10 and interferon-gamma plasma levels in human visceral leishmaniasis: implications in the pathogenesis. BMC Infect Dis 2005; 5: 113.
16. Ghalib HW, Piuvezam MR, Skeiky YA, et al. Interleukin 10 production correlates with pathology in human Leishmania donovani infections. J Clin Invest 1993; 92: 324-329.
17. Bacellar O, D'Oliveira A Jr, Jeronimo S & Carvalho EM. IL-10 and IL-12 are the main regulatory cytokines in visceral leishmaniasis. Cytokine 2000; 12: 1228-1231.
18. Murphy ML, Wille U, Villegas EN, Hunter CA & Farrell JP. IL-10 mediates susceptibility to Leishmania donovani infection. Eur J Immunol 2001; 31: 2848-2856.
19. Peruhype-Magalhaes V, Martins-Filho OA, Prata A, et al. Mixed inflammatory ? regulatory cytokine profile marked by simultaneous raise of interferon-gamma and interleukin-10 and low frequency of tumour necrosis factor-alpha(+) monocytes are hallmarks of active human visceral leishmaniasis due to Leishmania chagasi infection. Clin Exp Immunol 2006; 146: 124-132.
20. Chisari FV. Immunoregulatory properties of human plasma in very low density lipoproteins. J Immunol 1977; 119: 2129-2136.
21. Soares NM, Ferraz TP, Nascimento EG, Carvalho EM & Pontes-de-Carvalho L. The major circulating immunosuppressive activity in American visceral leishmaniasis patients is associated with a high-molecular weight fraction and is not mediated by IgG, IgG immune complexes or lipoproteins. Microb Pathog 2006; 40: 254-260.
22. Girona J, La Ville AE, Heras M, Olive S & Masana L. Oxidized lipoproteins including HDL and their lipid peroxidation products inhibit TNF-alpha secretion by THP-1 human macrophages. Free Radic Biol Med 1997; 23: 658-667.
23. Fessel WJ, Follansbee SE & Rego J. High-density lipoprotein cholesterol is low in HIV-infected patients with lipodystrophic fat expansions: implications for pathogenesis of fat redistribution. AIDS 2002; 16: 1785-1789.
24. Fernandez-Miranda C, Pulido F, Carrillo JL, et al. Lipoprotein alterations in patients with HIV infection: relation with cellular and humoral immune markers. Clin Chim Acta 1998; 274: 63-70.
25. Ramos TM, de Vasconcelos AS, de Carvalho VC & Lima VL. Alterations in cholesterol, triglyceride and total phospholipid levels in plasma of Callithrix jacchus (sagui) reinfected by Schistosoma mansoni. Rev Soc Bras Med Trop 2004; 37: 37-40.
26. Nieto CG, Barrera R, Habela MA, et al. Changes in the plasma concentrations of lipids and lipoprotein fractions in dogs infected with Leishmania infantum. Vet Parasitol 1992; 44: 175-182.
27. Bekaert ED, Dole E, Dubois DY, et al. Alterations in lipoprotein density classes in infantile visceral leishmaniasis: presence of apolipoprotein SAA. Eur J Clin Invest 1992; 22: 190-199.
28. Bekaert ED, Kallel R, Bouma ME, et al. Plasma lipoproteins in infantile visceral leishmaniasis: deficiency of apolipoproteins A-I and A-II. Clin Chim Acta 1989; 184: 181-191.
29. Bertoli A, Greco AV, Caputo S, Caradonna P, Grieco A & Laghi V. Visceral leishmaniasis presenting with hypertrigliceridaemia. Lancet 1982; 2: 504-505.
30. Liberopoulos E, Alexandridis G, Bairaktari E & Elisaf M. Severe hypocholesterolemia with reduced serum lipoprotein(a) in a patient with visceral leishmaniasis. Ann Clin Lab Sci 2002; 32: 305-308.
31. Gatfield J & Pieters J. Essential role for cholesterol in entry of mycobacteria into macrophages. Science 2000; 288: 1647-1650.
32. Lauer S, VanWye J, Harrison T, et al. Vacuolar uptake of host components, and a role for cholesterol and sphingomyelin in malarial infection. EMBO J 2000; 19: 3556-3564.
33. Jutras I, Abrami L & Dautry-Varsat A. Entry of the lymphogranuloma venereum strain of Chlamydia trachomatis into host cells involves cholesterol-rich membrane domains. Infect Immun 2003; 71: 260-266.
34. Seveau S, Bierne H, Giroux S, Prevost MC & Cossart P. Role of lipid rafts in E-cadherin - and HGF-R ? Met - mediated entry of Listeria monocytogenes into host cells. J Cell Biol 2004; 166: 743-753.
35. Tewary P, Veena K, Pucadyil TJ, Chattopadhyay A & Madhubala R. The sterol-binding antibiotic nystatin inhibits entry of non-opsonized Leishmania donovani into macrophages. Biochem Biophys Res Commun 2006; 339: 661-666.
36. Rodriguez NE, Gaur U & Wilson ME. Role of caveolae in Leishmania chagasi phagocytosis and intracellular survival in macrophages. Cell Microbiol 2006; 8: 1106-1120.
37. Pucadyil TJ & Chattopadhyay A. Cholesterol: a potential therapeutic target in Leishmania infection? Trends Parasitol 2007; 23: 49-53.
38. Chakraborty D, Banerjee S, Sen A, Banerjee KK, Das P & Roy S. Leishmania donovani affects antigen presentation of macrophage by disrupting lipid rafts. J Immunol 2005; 175: 3214-3224.
39. Voller A, Bartlett A & Bidwell DE. Enzyme immunoassays with special reference to ELISA techniques. J Clin Pathol 1978; 31: 507-520.
40. Redgrave TG, Roberts DC & West CE. Separation of plasma lipoproteins by density-gradient ultracentrifugation. Anal Biochem 1975; 65: 42-49.
41. Nanjee MN, Cooke CJ, Olszewski WL & Miller NE. Lipid and apolipoprotein concentrations in prenodal leg lymph of fasted humans. Associations with plasma concentrations in normal subjects, lipoprotein lipase deficiency, and LCAT deficiency. J Lipid Res 2000; 41: 1317-1327.
42. Kallel R, Bekaert ED, Dubois DY, Alcindor LG, Ayrault-Jarrier M & Mebazza A. Acute phase proteins and plasma lipoproteins during antimony treatment in infantile visceral leishmaniasis. Clin Physiol Biochem 1993; 10: 8-12.
43. Miles SA, Conrad SM, Alves RG, Jeronimo SM & Mosser DM. A role for IgG immune complexes during infection with the intracellular pathogen Leishmania. J Exp Med 2005; 201: 747-754.
44. Meddeb-Garnaoui A, Zrelli H & Dellagi K. Effects of tropism and virulence of Leishmania parasites on cytokine production by infected human monocytes. Clin Exp Immunol 2009; 155: 199-206.
45. Chandra D & Naik S. Leishmania donovani infection down-regulates TLR2-stimulated IL-12p40 and activates IL-10 in cells of macrophage ? monocytic lineage by modulating MAPK pathways through a contact-dependent mechanism. Clin Exp Immunol 2008; 154: 224-234.
46. Nylen S, Maurya R, Eidsmo L, Manandhar KD, Sundar S & Sacks D. Splenic accumulation of IL-10 mRNA in T cells distinct from CD4+CD25+ (Foxp3) regulatory T cells in human visceral leishmaniasis. J Exp Med 2007; 204: 805-817.
47. Green SJ, Mellouk S, Hoffman SL, Meltzer MS & Nacy CA. Cellular mechanisms of nonspecific immunity to intracellular infection: cytokine-induced synthesis of toxic nitrogen oxides from L-arginine by macrophages and hepatocytes. Immunol Lett 1990; 25: 15-19.
48. Theodos CM, Povinelli L, Molina R, Sherry B & Titus RG. Role of tumor necrosis factor in macrophage leishmanicidal activity in vitro and resistance to cutaneous leishmaniasis in vivo. Infect Immun 1991; 59: 2839-2842.
49. Moore KJ & Matlashewski G. Intracellular infection by Leishmania donovani inhibits macrophage apoptosis. J Immunol 1994; 152: 2930-2937.
50. Gorak PM, Engwerda CR & Kaye PM. Dendritic cells, but not macrophages, produce IL-12 immediately following Leishmania donovani infection. Eur J Immunol 1998; 28: 687-695.
51. Delfino D, Chiofalo MS, Riggio G, et al. Induction of interleukin 1 alpha in murine macrophages infected in vitro with different species and strains of Leishmania. Microb Pathog 1995; 18: 73-80.
52. Veress B, Omer A, Satir AA & El Hassan AM. Morphology of the spleen and lymph nodes in fatal visceral leishmaniasis. Immunology 1977; 33: 605-610.
53. Chulay JD & Bryceson AD. Quantitation of amastigotes of Leishmania donovani in smears of splenic aspirates from patients with visceral leishmaniasis. Am J Trop Med Hyg 1983; 32: 475-479.
54. Engwerda CR, Ato M & Kaye PM. Macrophages, pathology and parasite persistence in experimental visceral leishmaniasis. Trends Parasitol 2004; 20: 524-530.
55. Chan SH, Kobayashi M, Santoli D, Perussia B & Trinchieri G. Mechanisms of IFN-gamma induction by natural killer cell stimulatory factor (NKSF ? IL-12). Role of transcription and mRNA stability in the synergistic interaction between NKSF and IL-2. J Immunol 1992; 148: 92-98.
56. Manetti R, Gerosa F, Giudizi MG, et al. Interleukin 12 induces stable priming for interferon gamma (IFN-gamma) production during differentiation of human T helper (Th) cells and transient IFN-gamma production in established Th2 cell clones. J Exp Med 1994; 179: 1273-1283.
57. Nau GJ, Schlesinger A, Richmond JF & Young RA. Cumulative Toll-like receptor activation in human macrophages treated with whole bacteria. J Immunol 2003; 170: 5203-5209.
58. Van Weyenbergh J, Santana G, D'Oliveira A Jr, et al. Zinc ? copper imbalance reflects immune dysfunction in human leishmaniasis: an ex vivo and in vitro study. BMC Infect Dis 2004; 4: 50.
59. Rosa R, Rodrigues OR, Marques C & Santos-Gomes GM. Leishmania infantum: soluble proteins released by the parasite exert differential effects on host immune response. Exp Parasitol 2005; 109: 106-114.
60. Jeronimo SM, Holst AK, Jamieson SE, et al. Genes at human chromosome 5q31.1 regulate delayed-type hypersensitivity responses associated with Leishmania chagasi infection. Genes Immun 2007; 8: 539-551.